Business Wire

TA Associates to Invest in Compusoft

11.7.2018 08:00:00 EEST | Business Wire | Press release

Share

TA Associates, a leading global growth private equity firm, today announced that it has entered into a definitive agreement to invest in Compusoft, a leading provider of computer-aided design (“CAD”) software to the kitchen and bathroom retail industries. The investment is expected to close in the third quarter of 2018. Financial terms of the transaction were not disclosed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180710006074/en/

Compusoft’s main products, Winner Design and Innoplus, provide design and sales support to kitchen and bathroom retailers, respectively. The user-friendly CAD systems include proprietary databases of graphic elements, pricing information and language translations from more than 2,800 digital manufacturer catalogues. They also feature fully-integrated graphics displayed in real‐time 3D. Additional Compusoft products allow individuals to easily design and view kitchens or bathrooms in 3D on a smartphone or tablet. The company also offers back-office customer relationship management (CRM) and process management software systems for small and large businesses. Founded in 1989 in Sarpsborg, Norway, Compusoft operates in 14 countries across Europe, as well as South Africa and Australia, and serves approximately 12,000 customers, including leading global manufacturers and retailers.

“Compusoft is among the industry leaders in Europe, with a high quality business model and an impressive history of sustained growth,” said Naveen Wadhera, a Managing Director at TA Associates who will join the Compusoft Board of Directors. “We look forward to partnering with Compusoft, which fits squarely within our focus on profitable businesses with strong management teams and proprietary products and services, to help the company capitalize on its strategy and accelerate growth.”

“Given our mission to create measurable added value for our customers, we believe TA Associates, with their well-earned reputation for helping businesses reach their full potential, is an ideal partner for Compusoft,” said David Tombre, Chief Executive Officer, Compusoft. “We have enjoyed notable organic and acquisitive growth over the course of our nearly 30-year history and are confident that TA can help us build on that success. We welcome the opportunity to work with TA as we explore opportunities for continued expansion.”

“As the demand for kitchen and bathroom modeling services continues to rise, we expect interest in Compusoft’s unique offerings and capabilities to expand further across Europe and other regions,” said J. Morgan Seigler, a Managing Director at TA Associates who will also join the Compusoft Board of Directors. “Importantly, Compusoft’s innovative technology provides customers with a user-friendly experience to develop fully-customized spaces to meet their individual needs and desires. With the company’s leading market position, we anticipate continued meaningful growth for Compusoft.”

Goodwin is providing legal counsel, while Alvarez & Marsal and KPMG are providing consulting services to TA Associates. Kvale is providing legal counsel and ABG Sundal Collier is serving as financial advisor to Compusoft.

About Compusoft
Founded in 1989 in Sarpsborg, Norway, Compusoft provides sales, management, communication, web and business solutions for the kitchen and bath industry. The company’s advanced CAD software solutions offer dynamic sales tools for retailers, helping them lead customers through the entire planning process, from sketch to fully installed kitchen or bath. With a focus on creating added value for its customers, Compusoft combines the development of high-quality software with a dedication to customer service. Compusoft operates in 14 countries across Europe, as well as South Africa and Australia. For more information, please visit www.compusoftgroup.com.

About TA Associates
Now in its 50th year, TA Associates is one of the largest and most experienced global growth private equity firms. Focused on five target industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in nearly 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in growth companies. TA has raised $24 billion in capital since its founding in 1968 and is committing to new investments at the pace of $1.5 to $2 billion per year. The firm’s more than 80 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA Associates can be found at www.ta.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

TA Associates
Marcia O’Carroll, 617-574-6796
mocarroll@ta.com
or
BackBay Communications
Stephen Fishleigh, +44-203-475-7552
stephen.fishleigh@backbaycommunications.com
or
Zachary Tramonti, 617-391-0797
zachary.tramonti@backbaycommunications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye